CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells $50,819.16 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 1,198 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CRISPR Therapeutics Price Performance

CRSP traded up $1.12 on Wednesday, reaching $43.49. 1,399,700 shares of the company’s stock were exchanged, compared to its average volume of 2,256,949. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $76.86. The stock has a market cap of $3.73 billion, a PE ratio of -9.95 and a beta of 1.77. The stock’s fifty day moving average price is $43.02 and its 200-day moving average price is $45.65.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Wood Tarver Financial Group LLC acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $30,000. Ameriflex Group Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter worth about $36,000. GF Fund Management CO. LTD. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $71,000. Sunbelt Securities Inc. boosted its position in CRISPR Therapeutics by 108.6% in the 4th quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock valued at $238,000 after buying an additional 3,210 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in CRISPR Therapeutics by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock worth $27,166,000 after purchasing an additional 13,865 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Thursday, February 13th. Royal Bank of Canada cut their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. Evercore ISI raised CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.